TipRanks
Go Ultimate55% OFF

Compare Fisher & Paykel Healthcare Corporation Limited (FSPKF) vs. Competitors

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
FSPKFFisher & Paykel Healthcare Corporation Limited$27.01$15.73B59.5828.93%Strong BuyUnlock the FSPKF analyst price target with TipRanks PremiumFSPKFUnlock the FSPKF top-analyst price target with TipRanks Premium
NZ:EBOEBOS Group LimitedNZD 21.29NZD 4.29B15.33-29.16%Strong BuyUnlock the NZ:EBO analyst price target with TipRanks PremiumFSPKF vs NZ:EBOUnlock the NZ:EBO top-analyst price target with TipRanks Premium
NZ:PEBPacific Edge LimitedNZD 0.24NZD 291.84M-6.1325.67%―Unlock the NZ:PEB analyst price target with TipRanks PremiumFSPKF vs NZ:PEBUnlock the NZ:PEB top-analyst price target with TipRanks Premium
NZ:RYMRyman HealthcareNZD 1.79NZD 1.80B-10.76-38.33%Moderate BuyUnlock the NZ:RYM analyst price target with TipRanks PremiumFSPKF vs NZ:RYMUnlock the NZ:RYM top-analyst price target with TipRanks Premium
NZ:TRUTruScreen Group Ltd.NZD 0.01NZD 9.43M-2.90-47.37%―Unlock the NZ:TRU analyst price target with TipRanks PremiumFSPKF vs NZ:TRUUnlock the NZ:TRU top-analyst price target with TipRanks Premium
NZ:AFTAFT Pharmaceuticals Ltd.NZD 4.60NZD 487.67M32.8852.46%Moderate BuyUnlock the NZ:AFT analyst price target with TipRanks PremiumFSPKF vs NZ:AFTUnlock the NZ:AFT top-analyst price target with TipRanks Premium

Performance Comparison

-50%-25%0%25%50%75%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
FSPKFFisher & Paykel Healthcare Corporation Limited27.016.0628.93%
NZ:EBOEBOS Group Limited20.50-6.83-24.99%
NZ:PEBPacific Edge Limited0.230.0421.76%
NZ:RYMRyman Healthcare1.77-1.10-38.33%
NZ:TRUTruScreen Group Ltd.0.01-0.01-47.37%
NZ:AFTAFT Pharmaceuticals Ltd.4.651.6253.67%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts